Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean‐Pascal Machiels, Ana Paula Victorina, Lisa Licitra et al.|The Lancet Oncology|2024Cited by 223